Abiopharma

🔍 Golman Jeffrey A (Director)

Company: MONROE CAPITAL Corp (MRCC)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Sold 20,356 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: Disposed of upon the completion of, and pursuant to, the transactions contemplated by the Agreement and Plan of Merger, dated as of August 7, 2025, by and among Horizon Technology Finance Corporation ("HRZN"), a Delaware corporation, Monroe Capital Corporation ("MRCC"), a Maryland corporation, HMMS, Inc., a Maryland corporation, Monroe Capital BDC Advisors, LLC, a Delaware limited liability company, and Horizon Technology Finance Management LLC, a Delaware limited liability company (the "Merger Agreement"). Pursuant to the Merger Agreement, each share of MRCC common stock, par value $0.001 per share, was converted into the right to receive 0.9402 shares of HRZN common stock, par value $0.001 per share. The market price of HRZN common stock at the close of trading on April 13, 2026, the last trading day prior to closing of the merger, was $4.57.